WGS
GeneDx Holdings Corp.
Diagnostics & Research · Healthcare · United States
79.15
close · 2026-08-13
value
21
cheaper than peers21
quality
20
stronger fundamentals20
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| price to sales | 4.75× | 54 |
| price to book | 9.24× | 29 |
| forward P/E | 67.72× | 8 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 17.4% | 66 |
| debt to equity | 66.2% | 44 |
| operating margin | -25.6% | 17 |
| return on equity | -30.4% | 13 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $3.6M |
| employees | 1,300 |
| first trade | 2020-11-04 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-04 |